DBS Bank Mandiri:Buy; Rp6,350; TP Rp7,000; BMRI IJ

Appointed bookrunners and underwriter for rights issue

BMRI appointed Deutsche Bank, BofA-Merrill Lynch, Citi and CLSA as joint bookrunners and Danareksa as underwriter for corporate rights issue purpose. BMRI targets to conduct rights issue before year end in anticipation to meet capital demand as lending grows more than 20% this year. The bank projects to gather Rp13tr proceed to increase CAR and secure 5ppt tax reduction incentive. As a preliminary step, BMRI held non-deal roadshow with 50 prospective investors in Hong Kong and Singapore last month to gauge market interest on rights issue shares.

DBS Bank Mandiri: Buy; Rp5,900; TP Rp7,000; BMRI IJ

Green NPL recovery target achievement

Bank Mandiri (BMRI) would like to close the year, achieving its loan recovery target of Rp1tr. Till July 2010, BMRI has managed to book NPL recovery of Rp700bn or 70% of annual target. In addition, BMRI plans to book around Rp279-290bn from Benua Indah’s loan collaterals auction in September. Benua Indah has been a big debtor since crisis era in 1998 with total outstanding loan of Rp480bn. On top of that, BMRI has reached agreement with Bakrie Sumatra Plantations (UNSP) to sell Domba Mas where UNSP has paid Rp935bn as first installment of acquisition price in June. Domba Mas has indebted to BMRI for Rp3.3tr. However, the acquisition negotiation progress with UNSP has been put off. It is reported that BMRI will cancel the agreement and look for other investors should UNSP not finalize its commitment. BMRI is also restructuring 20 debtors including Garuda Indonesia which will execute its IPO plan in November. Therefore, BMRI will sell its stake in Garuda Indonesia and book proceeds from IPO this year.

DBS Bank Mandiri: Buy; Rp6,100; TP Rp7,000; BMRI IJ

Picking up steam

At a Glance
* 2Q10 net profit of Rp2,031m in line
* Loan growth picked up as expected (+8% q-o-q), while NIM expanded marginally to 5.2%
* Maintain Buy and Rp7,000 TP

Comment on Result
2Q10 net profit of Rp2,031m (+1% q-o-q, +33% y-o-y) was driven by higher non-interest income arising largely from treasury, as enhanced infrastructure and innovative payment solutions boosted transaction fees. Earnings are now more balanced with acceleration in micro, retail and consumer finance, instead of its legacy dependency on corporate loans. NIM inched up to 5.2% in 2Q10 as asset yields improved with strong growth of micro and consumer loans while cost of funds remained
flat. Loan growth was broad-based and strong at 8% q-o-q in 2Q10 (YTD: 10%), while deposits grew 4% (YTD: flat), bringing loan-to-deposit ratio to 66.3%. CASA-to-total deposit was stable at 57%. Operating costs were contained with cost-to-income ratio at 38%. NPL ratio was 2.5% while loan loss coverage remained high at 206% despite marginal downgrade of some commercial loans in its performing loan book. CAR fell to 14.6% (CAR ex-operating risk: 15.3%) along with loan growth, and is expected
to strengthen as BMRI prepares for its rights issue in 4Q10. BMRI has received the Finance Ministry's approval and is now requesting approval from parliament. We expect loan growth to accelerate again in 2H10 driven mainly by high yielding micro and consumer loans (including vehicle financing). BMRI would benefit if the BI rate is raised in 2H10 given most of its assets (largely government bonds) carry variable
rates, and it has a strong CASA base. Based on our sensitivity analysis, every 25bps BI rate hike would raise earnings by 3.1%.

Recommendation
BMRI remains our top pick. Our TP is maintained at Rp7,000 based on the Gordon Growth Model (implying 3x FY11 BV and 13.9x FY11 EPS) with the following assumptions: 25% sustainable ROE, 10% long-term growth and 15% cost of equity. The recovery of selected key NPLs, including Garuda (towards 4Q10), Argo Manunggal and Domba Mas, is on track. Our estimates do not incorporate the recoveries and tax benefits, which means there could be 12-15% upside to our forecast earnings.